Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page
- Check7 days agoChange DetectedPage revision tag updated from v3.5.4 to v3.5.5, indicating a maintenance/patch-level update to the page. This change does not alter the visible content or behavior of the page.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page shows a new revision tag, v3.5.4, replacing the previous v3.5.3, indicating a small update to the document version. The change affects metadata only and does not modify study details or results.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page’s site “Revision” indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision upgraded from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check85 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0; no substantive study information changes are evident.SummaryDifference0.1%

- Check92 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.